Research and Markets: Following On From Keppras Commercial Success, UCB Is the Current Epilepsy Market Leader - Read More inside 'Epilepsy - Pipeline Drugs Struggle To Outshine Their Marketed Predecessors'.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45261) has announced the addition of Pipeline Insight: Epilepsy - Pipeline Drugs Struggle to Outshine out·shine v. out·shone , out·shin·ing, out·shines v.tr. 1. a. To shine brighter than. b. To be more beautiful, splendid, or flamboyant than. 2. their Marketed Predecessors to their offering. Slow generic uptake, reformulations, follow-on products and new market entrants will ensure steady long-term growth of the epilepsy market despite several high profile patent expiries. UCB UCB - University of California at Berkeley has emerged as the number one epilepsy company, and is set to strengthen their epilepsy pipeline if the proposed acquisition of Schwarz is confirmed. Scope of this title: - Analysis of patient potential, unmet needs and clinical trial design in epilepsy - Overview of drugs in pre-registration, Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA , II and I; with analysis of key companies involved in the market - Detailed profiles of key compounds in development for use in epilepsy, with forecasts of drug revenues to 2015 - Discussion of UCB, Eisai, and GSKs strategies and insight from key industry opinion leaders Highlights of this title: Following on from Keppras commercial success, UCB is the current epilepsy market leader. UCB's existing relationship with neurologists will bode bode 1 v. bod·ed, bod·ing, bodes v.tr. 1. To be an omen of: heavy seas that boded trouble for small craft. 2. well for the potent follow-on compounds, brivaracetam and seletracetam. UCB's proposed acquisition of Schwarz will further boost its epilepsy pipeline and CNS See Continuous net settlement. CNS See continuous net settlement (CNS). marketing/sales capabilities. If the acquisition is completed, the author believes that UCB will continue to develop Schwarzs Phase III pipeline product lacosamide. Generic incursion in·cur·sion n. 1. An aggressive entrance into foreign territory; a raid or invasion. 2. The act of entering another's territory or domain. 3. in the epilepsy market is less profound than in other CNS sectors. Nevertheless, lifecycle management strategies will be necessary to maintain market share following patent expiries. For example, development of sustained release/extended release formulations such as GSKs Lamictal XR can slow generic incursion. Reasons to read a copy: - Understand unmet needs in the epilepsy market based on key opinion leader comments - Benchmark key late-stage epilepsy compounds against current market leaders - Assess the global (US, Japan, five major EU) sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. of key late-stage pipeline drugs; and examine their clinical and commercial potential Chapter Outline: Chapter 1. Executive summary Chapter 2. Patient potential Chapter 3. R&D approach Chapter 4. Epilepsy pipeline analysis Chapter 5. Gabaergic modulators: late-stage drug analysis and forecasts Chapter 6. Ion channel ion channel n. See channel. modulators: late-stage drug analysis and forecasts Chapter 7. Glutamate glutamate /glu·ta·mate/ (gloo´tah-mat) a salt of glutamic acid; in biochemistry, the term is often used interchangeably with glutamic acid. glu·ta·mate n. 1. A salt of glutamic acid. modulators: late-stage analysis and forecasts Chapter 8. Other late-stage products in clinical development Chapter 9. Innovative early-stage projects BIBLIOGRAPHY Journal articles and conference abstracts Websites APPENDIX A APPENDIX B List of Tables List of Figures For more information visit http://www.researchandmarkets.com/reports/c45261 Source: Datamonitor |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion